New Drug for Mismatch Repair Deficient Endometrial Cancer and Solid Tumors
The Food and Drug Administration (FDA) has granted accelerated approval to dostarlimab-gxly (Jemperli) for the treatment of adults with mismatch repair deficient recurrent or advanced endometrial cancer and solid tumors.
Source: AJN - Category: Nursing Tags: Drug Watch Source Type: research
More News: Cancer | Cancer & Oncology | Endometrial Cancer | Food and Drug Administration (FDA) | Gastroschisis Repair | Nursing